Background: The anaesthetic conserving device, AnaConDa ® , allows use of inhaled anaesthetics for sedation in the intensive
Editor′s key points
• The AnaConDa device facilitates the administration of inhalation agents for ICU sedation.
• Uncertainty exists about the safety of inhalation sedation in patients with neurological injuries.
• The Anaconda was used to administer sevoflurane sedation to stroke and subarachnoid haemorrhage victims.
• Many patients developed decreases in cerebral perfusion pressure and some raised intracranial pressure.
With the introduction of an anaesthetic conserving device (AnaConDa ® ) in 2005, the use of sevoflurane for ICU sedation has become practical and technically feasible. 1 Experimental animal research indicating that volatile anaesthetics may induce ischaemic preconditioning and have neuroprotective effects has sparked interest in the use of such agents for neurocritical care unit (NCCU) sedation. 2 However, reports on the danger of increasing intracranial pressure (ICP) as a result of cerebral vasodilation has discouraged their use for years. 2 With regard to sevoflurane, reports on its influence on cerebral haemodynamics are contradictory and focus on general anaesthesia for surgical procedures instead of sedation in a (neuro)intensive care environment. As a result, the safety and feasibility of sevoflurane for sedation in the NCCU is unclear. [3] [4] [5] [6] [7] [8] [9] [10] With a more widespread administration of sevoflurane to ICU patients with primary or secondary brain injury, potential benefits as well as harms might go unnoticed if multimodality neuromonitoring is not utilized. To clarify the potential benefits and safety concerns regarding sevoflurane sedation, we prospectively analysed the switch from i.v. sedation to inhaled sevoflurane sedation administered via AnaConDa ® in ventilated critical care stroke patients under multimodality monitoring. We assessed the short-and long-term effects on cerebral and systemic haemodynamics, oxygenation, and respiratory parameters.
Methods

Study setting and patient selection
Approval of the responsible Ethics Committee Heidelberg (S-188/ 2009) was obtained before starting this prospective, singlecentre, observational study. Patients admitted to the Heidelberg University Hospital NCCU between March 2010 and December 2011 (thereafter, our in-house sedation protocol was changed) were screened. Inclusion criteria were: (I) acute cerebrovascular event (ischaemic stroke (IS), intracerebral haemorrhage (ICH), or subarachnoid haemorrhage (SAH)); (II) mechanical ventilation; (III) multimodality neuromonitoring as indicated by the attending physician (at least continuous ICP monitoring and Doppler capacity); and (IV) written informed consent of the patient's legal representative (for study participation and anonymous publication). Exclusion criteria were: (I) severely impaired pulmonary gas exchange (e.g., partial arterial oxygen pressure ðPa O2 Þ <8 kPa (60 mm Hg) despite fractional inspiratory oxygen ðFI O2 Þ > 0:6 and PEEP >10 cm H 2 O); (II) refractory ICP crises (>25 mm Hg) lasting longer than 5 min and not responding to osmotherapy; (III) history or family history of malignant hyperthermia; and (IV) inclusion in any other trial influencing the sedation regime.
Ventilation and sedation
We used the pressure-controlled ventilation mode via SERVO-s Patients were initially sedated with propofol or midazolam (in patients with propofol-induced hypotension) in combination with an opoid analgesic drug (remifentanil or sufentanil) according to our in-house standard. The Richmond Agitation Sedation Scale (RASS) was used to monitor the depth of sedation during the whole NCCU stay (target range −5 to −4 during the first days of the acute disease and in the study period). Sevoflurane was administered using AnaConDa ® (technical details are described in 1 11 12 ). Briefly, the AnaConDa ® syringe was filled with sevoflurane, before connecting the device between the patient and respirator. It was filled with a 1.5 ml bolus, and additional 0.1 ml boli were administered until gas was registered at the monitor. Airway sevoflurane concentration and expiratory CO 2 were measured and minimum alveolar concentration (MAC) was calculated using a gas monitor (Scio Four Oxi plus, Dräger; Lübeck, Germany) connected to our standard monitoring system (Infinity Delta, Dräger; Lübeck, Germany 
Systemic monitoring
All vital signs and cardiorespiratory parameters were documented at least hourly during the transition period (−6 to +12 h). Heart rate (HR) was measured by using continuous ECG. Mean arterial pressure (MAP) was measured via a radial arterial line with the pressure sensor at the level of the heart. Partial arterial oxygen pressure ðPa O2 Þ, partial arterial carbon dioxide pressure ðPa CO2 Þ, pH, base excess (BE), and HCO 3 − were measured by blood gas analysis at least every other hour and arterial blood oxygen saturation ðSa O2 Þ was calculated from the blood gas measurements using Siemens™ RAPIDLab/Point ® (Siemens Healthcare GmbH, Eschborn, Germany). Central venous oxygen saturation ðScv O2 Þ was measured in blood drawn from a central line inserted in the internal jugular (n=22) or subclavian vein (n=3). Urinary bladder temperature was monitored. Respiratory rate (RR), PEEP, peak inspiratory pressure, fractional inspiratory oxygen ðFI O2 Þ, and minute volume (MV) were directly assessed from the respirator. Pulmonary oxygenation was calculated as Pa O2 =FI O2 .
Neuromonitoring
Patients were studied in the supine position with the head elevated by 20°during the sedation transition. A parenchymal probe (Neurovent-P As the MAP reference point was set to the level of the heart, the actual CPP level was estimated to be 5-10 mm Hg lower.
Mansfield, MA) and the cerebral arteriovenous oxygen saturation difference was calculated as Sa O2 À rS O2 . Fractional tissue oxygen extraction (FTOE) was calculated as ðSa O2 À rS O2 Þ=Sa O2 , as FTOE as the individual's oxygen extraction referencing to the individual patient's own arterial saturation has been found more robust and valid than the rS O2 on its own at least in paediatric patients. 15 The systemic arteriovenous oxygenation difference was calculated as Sa O2 À Scv O2 . Middle cerebral artery mean flow velocity (MFV) was measured by transtemporal duplex/Doppler sonography (LOGICe; GE Healthcare, München, Germany) and calculated as 1/3 (v systolic + 2v diastolic ). FTOE and MFV were separately calculated for the affected and nonaffected hemisphere. In patients whose lesions were bilateral or diffuse (such as in SAH), the side with more swelling and decompressive surgery was defined as 'affected' in two patients and the side of the aneurysm was defined as 'affected' in a third patient. Cerebrovascular resistance (CVR) was calculated as MAP/MFV for each hemisphere. FTOE and MFV, assessed bilaterally, and systemic oxygenation parameters were registered 1 h before and 1 h after the sedation switch, allowing systemic and ventilatory parameters to be kept mostly unchanged. ICP, MAP, and CPP were additionally measured and calculated at least hourly from 6 h before to 12 h after the sedation switch. All our in-house standard operating procedures for mechanical ventilation and weaning, normothermia, ICP and MAP/CPP management, and transfusion (target haemoglobin >8 g dl −1 )
were continuously applied during the study. We predefined the following safety values to trigger corrective measures: ICP >25 mm Hg, MAP <80 mm Hg, CPP <60 mm Hg, Sa O2 < 90%, Scv O2 < 70%, and rS O2 < 50% or 20% decrease from baseline.
Statistical analysis
Recorded and calculated parameters were described by mean (SD) or median (IQR); for categorical data we calculated absolute and relative frequencies (count and %). Shapiro-Wilk test was used to ascertain distribution of data. Measurements before and after the switch were compared by paired Student's t-test for normally distributed data and Wilcoxon's signed-rank test for not normally distributed. Unpaired t-test, Mann-Whitney U-test (for continuous variables) or the χ 2 test (for categorical data) were used to assess whether the distribution of baseline parameters differed between the patients who were successfully switched and those who were not. All P-values are descriptive and no adjustment for multiple comparisons was made; P < 0.05 is regarded significant. Explorative post-hoc analysis of subgroup differences was performed by repeated measures analysis of variance with time as the within-subject factor and diagnosis (or gender) as the between-subject factor. IBM™ SPSS ® Version 22 and GraphPad Prism (6.0b) were used for data analysis.
Results
Patients
Of 907 patients admitted to our NCCU, 177 received multimodality neuromonitoring and 152 were ventilated >24 h. 127 patients had to be excluded because they were either participating in other interventional trials (majority) or met at least one other exclusion criterion, resulting in 25 patients finally being included in the study (Table 1) .
Feasibility and safety
Initial sedatives were propofol in 16 patients, midazolam in 4 patients, and a combination of these in 5 patients. During transition to sevoflurane, 8 out of 25 patients (32%) displayed severe adverse reactions such as critical ICP elevations, forcing us to switch back to the initial i.v. sedative during the first 12 h after the switch. Sedation switch was done in successfully switched patients at day 3.8 (3.7), and in unsuccessfully switched at day 2.9 (2.5, P=0.545). The latter ones were excluded from our main analysis of long-and short-term effects, as AnaConDa ® use was stopped for safety concerns, and details of these patients are described separately (see below). The remaining majority of patients (n=17; 68%) continued with volatile sedation for 4.18 (2.53) days.
Short-term analysis
Comparing cerebrovascular and systemic parameters 1 h before to 1 h after the switch, we observed an increase in ICP [+2.4 (4.5) mm Hg; Fig. 1 , Table 3 ] also. This decrease in blood pressure occurred despite attempts to counteract it by increasing noradrenaline. Fluid in-and output did not change relevantly during the transition period. Analgesia with remifentanil was kept constant in most patients, but was switched to equivalent doses of sufentanil in two patients before switch (−5, −4 h), and in two patients after switch (+4, +10 h) of sedation. Pa CO2 was stabilized to near baseline by increasing MV (mainly by increasing the respiratory rate and at times by slightly increasing peak and mean inspiratory pressures, if still necessary). Blood gas analysis additionally revealed metabolic acidosis (Fig. 1 
Adverse reactions
In the 17 of 25 patients, cerebral and systemic parameters changed as described above, but remained inside tolerable thresholds. However, severe adverse reactions in eight other patients required early termination of sevoflurane administration. In one patient (#18 , Table 1 ), systolic blood pressure (SBP) could not be maintained above 100 mm Hg and it repeatedly decreased below 80 mm Hg, despite steadily increased vasopressor support. Although a MAC of 1.5 was reached, the patient developed ventilator-patient dyssynchrony and required concomitant administration of propofol and rocuronium. Sevoflurane sedation was 
Discussion
In this prospective study of sevoflurane sedation in 25 critical care patients with acute stroke or subarachnoid haemorrhage, sufficient sedation levels without clinically relevant ICP increase were achieved in 68% of the patients. However, serious adverse events observed in the remaining 32% raise considerable safety concerns.
In view of the heterogeneous literature regarding the amount of sevoflurane's cerebrovasodilatory effect and consequent ICP elevation, our own previous overall positive experience with the supposedly more vasodilatory isoflurane, and the ability to use multimodality monitoring, we have considered it justified to study a preselected population without prior refractory ICP crisis. 3 4-6 9 10 21 Indeed, in the 17 patients successfully switched to sevoflurane, ICP increased only slightly in the short term and remained stable in the long term. However, MAP and thus CPP decreased. Our findings are in line with other studies, finding that intraoperative sevoflurane anaesthesia decreased MAP 8 9 while ICP remained stable in some studies 5 22 and increased in others. 6 9 23 Our study adds the novel insight that significant and relevant MAP/CPP reductions and at least transient ICP elevations, possibly linked to increases in Pa CO2 , can already occur in the majority of patients at lower sedative doses of MAC (0.6 is typically sufficient in the ICU setting). We did not observe a consistent short-term change in MFV, supporting previous studies in which MFV was also not found to be influenced by sevoflurane. 24 25 In addition, we found that sevoflurane did not reduce FTOE (i.e., did not improve cerebral oxygenation) unlike our findings for isoflurane in a previous study. 21 One possible explanation for this discrepancy is that the dose of sevoflurane was not high enough to affect rS O2 , as a recent experimental trial in 44 patients undergoing abdominal hysterectomy found rS O2 to be higher only at considerably higher doses of sevoflurane (max. MAC 1.8).
26
Pa CO2 increased under use of AnaConDa ® , confirming experimental studies finding an increased CO 2 via AnaConDa ® 's enlarged dead space and CO 2 -conserving capacity. [27] [28] [29] [30] Efforts to keep Pa CO2 within the target levels required RR and MV to be increased significantly and, if still necessary, slightly higher peak and mean inspiratory pressures. In NCCU patients at risk for increased ICP, this effect of inhaled sedation underscores the necessity for tight control of Pa CO2 as increases in Pa CO2 may contribute to the short-term mean increase via hypercapnic vasodilatory effects. Notably, one third of the patients experienced severe adverse reactions: ICP increased rapidly and MAP decreased in five patients, forcing us to stop sevoflurane sedation (which reversed the changes). These findings differed from our previous experience with isoflurane. 21 We consider several explanations for the observed differences: (a) a high percentage of patients may have had a low baseline cerebral compliance (for instance, patients not tolerating the switch to sevoflurane had larger volumes of ICH (albeit statistically non-significant) and tended to require pre-switch osmotherapy more often (Table 4) ); (b) higher baseline ICP values in patients demonstrating adverse reactions decreased the safety margin, although these baseline ICP values were still within acceptable ranges; (c) as cerebral autoregulation is better preserved under sevoflurane than under isoflurane, 3 31 32 vasodilation responding to the decrease in MAP and a more intensive reaction to raised Pa CO2 might have caused ICP crises in patients with low cerebral compliance; and (d) although the hourly scored sedation depth was maintained at RASS −4 to −5 long-term, the sedation switch might have caused a transient stress response. We cannot rule out sympathetic activation which might have caused changes in cerebral metabolism and haemodynamics, but have not found conclusive evidence for it, as changes in minute volume were mainly the result of manual adjustments of ventilation parameters in order to achieve isocapnia, and heart rate did not change. As in the early termination group all parameters resolved to normal after sevoflurane was stopped and changed to a different sedative, we consider it unlikely that changes in the patients' condition itself could explain the observed adverse effects for the major part. Such drug-independent causes of the observed effects could theoretically have been for example increases in cerebral oedema, rebleeding, or seizures but no convincing hints at these conditions were present during the observational period in our population. We could not further elucidate the putative mechanisms underlying these adverse events, as we stopped administering sevoflurane for safety reasons. These findings were particularly worrying in retrospect, as 75% of the patients in the 'early termination' group had received standard sevoflurane anaesthesia during neurosurgery in the acute phase of their disease before this study (Table 1) . However, during neurosurgery no ICP/CPP monitoring was in place, thus impeding conclusions about cerebral pressure dynamics at that time.
As a consequence for our daily in-house sedation practice, the high incidence of ICP crises and other adverse reactions, together with higher cost and substance consumption, prompted us to abandon sevoflurane sedation in our NCCU. We continue to use isoflurane with the AnaConDa ® in selected patients under multimodality neuromonitoring (i.e. at least continuous monitoring of ICP and tight control of cardiopulmonary parameters). Our study has several limitations. It was conducted as a single-centre, open-label observational study and treatment allocation was not randomized. Thus, no confirmatory analysis was planned and the reported P-values should be interpreted as 35 We did not use bispectral index monitoring (BIS), which may have provided a more objective way to monitor sedation depth. Instead, the clinical RASS score, which correlates well with the BIS in NCCU patients, was used. 36 This is so far the largest prospective study in neurocritical care addressing feasibility and safety of sevoflurane administered via the AnaConDa ® . In conclusion, in a population of patients at high risk of intracranial hypertension, sevoflurane sedation was associated with major adverse events in one third of patients. In almost all of the patients, MAP had to be stabilized actively to maintain CPP. Based on these observations we do not feel that the alleged neuroprotective potential of sevoflurane outweighs the risk of adverse events and sevoflurane sedation should probably not be used in this specific patient population. If it is used, multimodality neuromonitoring is mandatory.
